Sarepta Therapeutics, Inc. (NASDAQ:SRPT) declined to $31.37 per share in the last trading day compared to a prior close of $32.63. The management team hold 0.4 percent of the stock. Barry Richard ranks as top insider in Sarepta Therapeutics, Inc., noted in the Company’s filings with the U.S. Securities and Exchange Commission. The insider’s stake of 3,241,014 shares is worth $102,000,000. Behrens M Kathleen is ranked No.2 with 112,166 shares as of Mar 16, 2016, which sits at a market value around $3,518,647. Kaye Edward M. Md is another big name in this category. This insider owns 72,635 SRPT shares, amounting to about $2,278,560 as of recent trading price which is 1.14% above its 20-day moving average and -2.31% below its 50-day moving average. The equity dropped -9.05% over the trailing 3 months.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in February 2017. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 7,335 shares of Sarepta’s common stock. The options have an exercise price of $31.11 per share, which is equal to the closing price of Sarepta’s common stock on February 28, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares closed at $3.35, down -0.12 points or -3.46 percent from  the previous close price. The up to date insider trading filings show Executive VP & CSO KELER TIBOR has picked up 3,000 shares,upping the ownership to 18,868 units. The transaction occurred on Sep 02, 2016, at $3.32 per share worth a total $9,960. There was another major transaction on the insider-trading front. CATLIN AVERY W, Sr. VP & CFO at CLDX bought 25,000 common shares at a per share price of $18 to hold 35,109 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 1.82M. The latest closing price is now lower -10.43% for the past quarter. The price is now -4.19% below its 50-day moving average and -14.49% below its 200-day moving average. The percentage change return over the last fifty two weeks remained -3.74%. The price range in the same period had a highest hit of $5.13 while lowest level in that period was $2.85.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) on March 1, 2017 announced the appointment of James J. Marino, J.D., to the Company’s Board of Directors. Mr. Marino was with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office. His practice focused on the representation of leading life sciences companies, both privately- and publicly-held, in a broad range of corporate, transactional and finance matters. He will serve as the Chairman of the Compensation Committee.

Mr. Marino currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center and on the Board of Directors of Onconova Therapeutics, Inc. He previously served on the Board of Directors of Pharmacopeia, Inc. He has also worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. Additionally, Mr. Marino is a co-founder of BioNJ, the trade association of biotechnology companies based in New Jersey, which he represented from its inception. Mr. Marino received his B.A., his M.B.A. and his J.D. from Rutgers University.